Using nanoparticles to deliver insulin orally for diabetes management
Oral delivery of insulin using ligand-directed nanoparticles that do not compete with physiological ligands
This study is exploring a new way to take insulin by mouth using tiny particles that help it work better, making it easier for people with type 2 diabetes to manage their blood sugar without needing injections.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama in Tuscaloosa NIH-funded |
| Lab location | 1 site (Tuscaloosa, United States) |
| Project ID | NIH-10580808 on NIH RePORTER |
What this research studies
This research investigates a novel method for delivering insulin orally using specially designed nanoparticles that do not interfere with the body's natural ligands. The approach aims to improve the absorption of insulin in patients with type 2 diabetes, potentially making it easier for them to manage their blood glucose levels without the need for injections. By focusing on enhancing the bioavailability of insulin through oral administration, the study seeks to provide a more patient-friendly treatment option. The methodology involves testing these nanoparticles in controlled environments to assess their effectiveness and safety.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with type 2 diabetes who require insulin management.
Not a fit: Patients with type 1 diabetes or those who do not require insulin therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more convenient and effective way for patients with type 2 diabetes to manage their insulin levels, improving their quality of life.
How similar studies have performed: While the use of nanoparticles for drug delivery is a growing field, this specific approach to oral insulin delivery is relatively novel and has not been extensively tested in previous studies.
Where this research is happening
Tuscaloosa, United States
- University of Alabama in Tuscaloosa — Tuscaloosa, United States (Active)
Researchers
- Principal investigator: Majeti, Ravikumar N — University of Alabama in Tuscaloosa
- Study coordinator: Majeti, Ravikumar N
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.